Bottom line: Imaging or operative records are key evidence
The study also showed that blood levels of CT-996 were largely unaffected either during fasting or after a standardized high-fat meal, suggesting the drug could potentially be dosed without regard to meal timing
Lustig RH, Greenway F, Velasquez-Mieyer PA, Heimberger D, Schumacher D, Smith D, Smith W, Soler N, Warsi G, Berg W, Maloney J, Benedetto J, Zhu W, Hohneker J: A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion
While complete adverse event data from most TRIUMPH trials is still pending full publication, early reported data aligns with Phase 2 observations